Advances in Virology / 2020 / Article / Fig 3

Research Article

HBV Core Promoter Inhibition by Tubulin Polymerization Inhibitor (SRI-32007)

Figure 3

Activity of SRI-32007 in the HBV infectious virus assay in HepG2-NTCP cells. HepG2-NTCP cells were treated with different concentrations of Myrcludex B (a) and SRI-32007 (b) either 0.5 hours before infection or 72 hours postinfection with HBV. HBe Ag levels (mean ± standard deviation) in the culture supernatant as measured by ELISA seven days postinfection normalized to the untreated virus controls are shown in the figure.
(a)
(b)

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.